NEUROCRINE POSTS THIRD-QUARTER PROFIT

Neurocrine Biosciences Inc., a developer of treatments for nervous and immune system disorders, posted a third-quarter profit Monday, as a payment from product partner Pfizer Inc. boosted revenue. The company also said it now expects a smaller loss for the year. Neurocrine recorded a profit of $26.2 million, or 68 cents per share, compared with a year-ago loss of $1.65 million, or 5 cents a share.

MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20051024&ID=5217746)